把三张表、经营指标、SEC / 巨潮 / 港交所原始财报、业绩材料和电话会放到同一条可核验时间线上。 披露事实、结构化补位值与派生指标分开标注,缺失逐字稿不会用摘要或模型生成内容补齐。
单季、累计、年度和资产负债表时点分开保存;每个数值都保留单位、申报日、表单、XBRL 概念或原始中文字段。
美股链接 SEC 法定申报和发行人 IR,A 股链接巨潮原始 PDF,港股链接港交所披露易原始年报与中报。分部、订单、产能和客户集中度只在有可核验披露时展示。
官方电话会入口与已授权逐字稿分开。没有合法取得的全文时只显示材料可用性,不生成或拼接虚假的逐字稿。
三张表会执行资产负债、毛利润、税前利润等勾稽检查;超出容差的记录保留原值并标记警告, 不会为了让公式“对上”而修改公司披露。
| 2026-03-31 |
| 3/3 |
| $1.88M |
| -$440.31M |
| -$5.59M |
| 23.7% |
| -833.2% |
| 87 |
| 尚无授权文本 |
| EOLS Evolus, Inc. | 2026-03-31 | 3/3 | $73.14M | -$10.67M | -$10.37M | 66.9% | -9.4% | 88 | 尚无授权文本 |
| EPM EVOLUTION PETROLEUM CORP | 2026-03-31 | 3/3 | $20.17M | -$8.93M | — | 35.7% | -2.8% | 81 | 尚无授权文本 |
| EVH Evolent Health, Inc. | 2026-03-31 | 3/3 | $496.25M | -$26.63M | — | 16.9% | -2.1% | 105 | 尚无授权文本 |
| EVLV Evolv Technologies Holdings, Inc. | 2026-03-31 | 3/3 | $46.33M | -$5.01M | — | 50.9% | -18.3% | 93 | 尚无授权文本 |
| EVMN Evommune, Inc. | 2026-03-31 | 3/3 | $0 | -$21.67M | -$27.59M | — | — | 13 | 尚无授权文本 |
| EVOX Evolution Global Acquisition Corp | 2026-03-31 | 3/3 | — | $1.95M | — | — | — | 9 | 尚无授权文本 |
| EVOXU Evolution Global Acquisition Corp | 2026-03-31 | 3/3 | — | $1.95M | — | — | — | 9 | 尚无授权文本 |
| GEVO Gevo, Inc. | 2026-03-31 | 3/3 | $42.95M | -$21.7M | -$30.02M | — | -11.4% | 119 | 尚无授权文本 |
| MEVO M Evo Global Acquisition Corp II | 2026-03-31 | 3/3 | — | -$6.99M | — | — | — | 4 | 尚无授权文本 |
| RVLV Revolve Group, Inc. | 2026-03-31 | 3/3 | $342.88M | $14.35M | $44.47M | 52.7% | 4.6% | 62 | 尚无授权文本 |
| RVMD Revolution Medicines, Inc. | 2026-03-31 | 3/3 | — | -$453.82M | -$355.7M | — | — | 85 | 尚无授权文本 |
| TVGN Tevogen Bio Holdings Inc. | 2026-03-31 | 3/3 | — | -$5.45M | — | — | — | 63 | 尚无授权文本 |
| EVGN Evogene Ltd. | 2025-12-31 | 2/3 | — | -$7.83M | — | — | — | 159 | 尚无授权文本 |
| EVO Evotec SE | 2024-12-31 | 2/3 | — | -$196.08M | — | — | — | 70 | 尚无授权文本 |